Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Filament Health Corp.
  6. News
  7. Summary
    FLHLF   CA31685W1068

FILAMENT HEALTH CORP.

(FLHLF)
  Report
Delayed OTC Markets  -  02:04 2022-12-08 pm EST
0.0503 USD   -52.10%
11/30Filament health announces new united states patent issuances
AQ
11/17Filament health announces psilocybin supply agreement with the centre for addiction and mental health
AQ
11/17Filament Health Announces Psilocybin Supply Agreement with the Centre for Addiction and Mental Health
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

FILAMENT HEALTH APPOINTS NEW MEMBERS TO BOARD OF DIRECTORS AND ADVISORY COUNCIL

08/24/2022 | 04:16pm EST

VANCOUVER, BC, Aug. 24, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Dr. Konstantin Adamsky of Negev Capital to its Board of Directors, and Jeff Chilton of Nammex to the Company's Advisory Council.

Konstantin Adamsky, PhD, is the Chief Operating Officer of Negev Capital, a psychedelic medical intervention investment fund that has made 20 investments to date. He has a long demonstrated track record in pharmaceutical R&D. Dr. Adamsky served as a VP Operations and Technology at Levco Pharmaceuticals Ltd, CEO and VP Operations at Regenera Pharma LTD, and Director and co-CEO at Targia Pharmaceuticals. He has also held positions at Compugen and the Weizmann Institute of Science. He is Co-founder and Director of Celleska Pty, Australian Cell & Gene Therapy Incubator. Dr. Adamsky holds a Ph.D from Weizmann Institute of Science, Israel.

Jeff Chilton is the Founder of Nammex, a company specialized in the development and manufacture of functional mushroom extract powders. Mr. Chilton studied ethnomycology at the University of Washington and in 1973 began a 10 year career as a large scale commercial mushroom grower. He is the co-author of the highly acclaimed book The Mushroom Cultivator. In 1989, Mr. Chilton established Nammex, the first company to supply medicinal mushroom extracts to the nutritional supplement industry. In 1997, he organized the first organic certification workshop for mushroom production in China, where 85% of the world's mushrooms are grown. Mr. Chilton is a founding member of the World Society for Mushroom Biology and Mushroom Products and a member of the International Society for Mushroom Science since 1978. He is also a council member of the International Society for Medicinal Mushrooms.

Filament's Chief Executive Officer, Benjamin Lightburn, commented: "We welcome the decades of industry knowledge and experience that Dr. Adamsky and Mr. Chilton will bring to Filament. Their appointments demonstrate the calibre of our platform and we look forward to gathering important insights from them both."

ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at www.filament.health and on Twitter, Instagram, and LinkedIn.

FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐ looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.

SOURCE Filament Health Corp.

© Canada Newswire, source Canada Newswire English

All news about FILAMENT HEALTH CORP.
11/30Filament health announces new united states patent issuances
AQ
11/17Filament health announces psilocybin supply agreement with the centre for addiction and..
AQ
11/17Filament Health Announces Psilocybin Supply Agreement with the Centre for Addiction and..
CI
11/10Filament Health Corp. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
11/10Filament health announces third quarter 2022 financial results and operational highligh..
AQ
10/12Filament health to host virtual investor update
AQ
09/01Filament health and atma journey centers announce 14 subjects dosed in health canada-ap..
AQ
09/01Filament Health Corp. and Atma Journey Centers Inc. Announce 14 Subjects Dosed in Healt..
CI
08/24Filament health appoints new members to board of directors and advisory council
AQ
08/24Filament Health Corp. Announces the Appointment of Dr. Konstantin Adamsky to Board of D..
CI
More news
Financials (USD)
Sales 2022 - - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -1,12x
Yield 2022 -
Capitalization 8,80 M 8,80 M -
Capi. / Sales 2022 -
EV / Sales 2023
Nbr of Employees 11
Free-Float 34,0%
Chart FILAMENT HEALTH CORP.
Duration : Period :
Filament Health Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,05 $
Average target price 1,50 $
Spread / Average Target 2 882%
EPS Revisions
Managers and Directors
Benjamin Lightburn Chief Executive Officer & Director
Warren Duncan Chief Financial Officer
James Gregory Mills Chairman
Ryan Moss Chief Science Officer
Lisa Ranken Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
FILAMENT HEALTH CORP.-77.86%9
THERMO FISHER SCIENTIFIC-14.88%223 800
DANAHER CORPORATION-18.47%197 875
INTUITIVE SURGICAL, INC.-24.29%96 128
BOSTON SCIENTIFIC CORPORATION7.42%66 345
SIEMENS HEALTHINEERS AG-24.89%58 366